BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013;33:727-36. [PMID: 23975654 DOI: 10.1007/s40261-013-0117-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Fourrier C, Sampson E, Mills NT, Baune BT. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials 2018;19:447. [PMID: 30126458 DOI: 10.1186/s13063-018-2829-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
2 Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet 2018;57:673-86. [PMID: 29189941 DOI: 10.1007/s40262-017-0612-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 20.0] [Reference Citation Analysis]
3 Baldwin DS, Hanumanthaiah VB. Vortioxetine in the treatment of major depressive disorder. Future Neurology 2015;10:79-89. [DOI: 10.2217/fnl.14.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 Hoffelt C, Gross T. A review of significant pharmacokinetic drug interactions with antidepressants and their management. Ment Health Clin 2016;6:35-41. [PMID: 29955445 DOI: 10.9740/mhc.2016.01.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
5 Areberg J, Petersen KB, Chen G, Naik H. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol 2014;115:552-9. [PMID: 24766668 DOI: 10.1111/bcpt.12256] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
6 Huang Y, Zheng S, Pan Y, Li T, Xu Z, Shao M. Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC–MS/MS: Application to their pharmacokinetic interaction study. Journal of Pharmaceutical and Biomedical Analysis 2016;128:184-90. [DOI: 10.1016/j.jpba.2016.05.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
7 Petruczynik A, Wróblewski K, Wojtanowski K, Mroczek T, Juchnowicz D, Karakuła-Juchnowicz H, Tuzimski T. Comparison of Various Chromatographic Systems for Identification of Vortioxetine in Bulk Drug Substance, Human Serum, Saliva, and Urine Samples by HPLC-DAD and LC-QTOF-MS. Molecules 2020;25:E2483. [PMID: 32471141 DOI: 10.3390/molecules25112483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chen G, Nomikos GG, Affinito J, Jacobson W, Zhao Z, Wang S, Xie J. Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Clinical Pharmacology in Drug Development 2018;7:880-8. [DOI: 10.1002/cpdd.577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:60-82. [PMID: 24165478 DOI: 10.1111/ijcp.12350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
10 Frederiksen T, Areberg J, Schmidt E, Bjerregaard Stage T, Brøsen K. Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine. Clin Pharmacol Ther 2021;109:150-9. [PMID: 32599653 DOI: 10.1002/cpt.1972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276. [PMID: 25260373 DOI: 10.1186/s12888-014-0276-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
12 Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother 2014;48:758-65. [PMID: 24676550 DOI: 10.1177/1060028014528305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
13 Berry-bibee EN, Kim M, Simmons KB, Tepper NK, Riley HE, Pagano HP, Curtis KM. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. Contraception 2016;94:650-67. [DOI: 10.1016/j.contraception.2016.07.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
14 Dhir A, Sarvaiya J. The efficacy of vortioxetine for the treatment of major depressive disorder. Expert Rev Neurother 2014;14:1349-63. [PMID: 25418918 DOI: 10.1586/14737175.2014.987131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
16 Douša M, Klvaňa R, Doubský J, Srbek J, Richter J, Exner M, Gibala P. HILIC–MS Determination of Genotoxic Impurity of 2-Chloro- N -(2-Chloroethyl)Ethanamine in the Vortioxetine Manufacturing Process. J Chromatogr Sci. [DOI: 10.1093/chromsci/bmv107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Le Corvaisier C, Capelle A, France M, Bourguignon L, Tod M, Goutelle S. Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction. Fundam Clin Pharmacol 2021;35:208-16. [DOI: 10.1111/fcp.12601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zheng J, Wang Z, Li E. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis. Afr Health Sci 2019;19:1716-26. [PMID: 31149002 DOI: 10.4314/ahs.v19i1.48] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Fu J, Chen Y. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis. Psychopharmacology (Berl) 2015;232:7-16. [PMID: 24871704 DOI: 10.1007/s00213-014-3633-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
20 Alcántara Montero A, Pacheco de Vasconcelos SR. Role of vortioxetine in the treatment of neuropathic pain. Rev Esp Anestesiol Reanim 2021:S0034-9356(21)00162-6. [PMID: 34243960 DOI: 10.1016/j.redar.2021.04.001] [Reference Citation Analysis]
21 Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. J Clin Psychopharmacol 2018;38:172-9. [DOI: 10.1097/jcp.0000000000000861] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
22 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
23 Salagre E, Grande I, Solé B, Sanchez-moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 2018;11:48-59. [DOI: 10.1016/j.rpsmen.2018.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
24 Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review. Drug Metab Dispos. 2014;42:1991-2001. [PMID: 25271211 DOI: 10.1124/dmd.114.060392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
25 Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016. Drug Metab Dispos 2018;46:835-45. [PMID: 29572333 DOI: 10.1124/dmd.117.078691] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
26 Patel K, Abdool PS, Rajji TK, Mulsant BH. Pharmacotherapy of major depression in late life: what is the role of new agents? Expert Opinion on Pharmacotherapy 2017;18:599-609. [DOI: 10.1080/14656566.2017.1308484] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
27 Connolly KR, Thase ME. Vortioxetine: a New Treatment for Major Depressive Disorder. Expert Opinion on Pharmacotherapy 2016;17:421-31. [DOI: 10.1517/14656566.2016.1133588] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 7.2] [Reference Citation Analysis]
28 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
29 Gu E, Huang C, Liang B, Yuan L, Lan T, Hu G, Zhou H. An UPLC–MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. Journal of Chromatography B 2015;997:70-4. [DOI: 10.1016/j.jchromb.2015.05.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
30 Chen G, Nomikos GG, Affinito J, Zhao Z. Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Clin Pharmacokinet 2016;55:1115-27. [PMID: 27048210 DOI: 10.1007/s40262-016-0389-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
31 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
32 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
33 Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics 2015;145:43-57. [DOI: 10.1016/j.pharmthera.2014.07.001] [Cited by in Crossref: 245] [Cited by in F6Publishing: 200] [Article Influence: 40.8] [Reference Citation Analysis]
34 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
35 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
36 Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism & Toxicology 2019;15:831-47. [DOI: 10.1080/17425255.2019.1669560] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
37 Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry 2021;:1-68. [PMID: 33977870 DOI: 10.1080/15622975.2021.1878427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Danielak D. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients? Expert Opin Pharmacother 2021;22:1167-77. [PMID: 33650935 DOI: 10.1080/14656566.2021.1880567] [Reference Citation Analysis]
39 de Diego M, Correa D, Mennickent S, Godoy R, Vergara C. Determination of vortioxetine and its degradation product in bulk and tablets, by LC-DAD and MS/MS methods. Biomed Chromatogr 2018;32:e4340. [PMID: 30001570 DOI: 10.1002/bmc.4340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Shamliyan TA, Middleton M, Borst C. Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs. Clin Ther 2017;39:404-427.e36. [PMID: 28189362 DOI: 10.1016/j.clinthera.2017.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
41 Matsuno K, Nakamura K, Aritomi Y, Nishimura A. Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Clin Pharmacol Drug Dev 2018;7:319-31. [PMID: 28941196 DOI: 10.1002/cpdd.381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
42 Douša M, Doubský J, Srbek J. Utilization of Photochemically Induced Fluorescence Detection for HPLC Determination of Genotoxic Impurities in the Vortioxetine Manufacturing Process. J Chromatogr Sci 2016;54:1625-30. [DOI: 10.1093/chromsci/bmw116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
43 Gibb A, Deeks ED. Vortioxetine: First Global Approval. Drugs 2014;74:135-45. [DOI: 10.1007/s40265-013-0161-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
44 Tritschler L, Felice D, Colle R, Guilloux J, Corruble E, Gardier AM, David DJ. Vortioxetine for the treatment of major depressive disorder. Expert Review of Clinical Pharmacology 2014;7:731-45. [DOI: 10.1586/17512433.2014.950655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
45 Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54. [PMID: 24570588 DOI: 10.2147/NDT.S39544] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]